| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 194.9 | 178.7 | 53.5 |
| Other income | 3.7 | 3.7 | 1.3 |
| Total income | 198.6 | 182.4 | 54.9 |
| Profit before exceptional items & tax | 9.9 | 9.8 | 9.2 |
| Profit before tax | 9.9 | 9.8 | 9.2 |
| Net profit | 10.5 | 7.9 | 6.3 |
| Operating margin | 5.0% | 5.4% | 16.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +66.70% |
|---|---|
| Net profit, quarter on quarter | +32.90% |
| Revenue, year on year | +264.30% |
| Operating profit, year on year | -21.50% |
| Operating profit, quarter on quarter | +1.60% |
BSE results filing, NSE: SAIPARENT. Figures extracted from the filing.
Sai Parenterals Ltd: key numbers
- Share price
- ₹521.95
- Market cap
- ₹2,306 Cr
- Revenue (annual)
- ₹381.0 Cr
- Net profit (annual)
- ₹14.26 Cr
- P/E (TTM)
- 111.0×Sector 45.9×
- Promoter holding
- 51.16%+0.00% QoQ
- FII holding
- 2.85%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sai Parenterals Ltd
All →Sai Parenterals Board Meeting Date
Sai Parenterals Ltd notified a Board Meeting on 1 Nov 2026 to approve unaudited Q2/H1 FY27 results. No financial figures or decisions are reported yet.
Sai Parenterals Acquisition Worth ₹15 Cr
Sai Parenterals Limited has acquired a 60% stake in Prathyak Laboratories Private Limited for ₹15 Crore. This acquisition provides an operational R&D facility in Hyderabad.
- Value
- ₹15.00 Cr
- product pipeline
- 150.0 SKUs
Sai Parenterals Other Announcement
Sai Parenterals Ltd submitted the Monitoring Agency Report for the quarter ended 30th June 2026 regarding the utilization of IPO proceeds, as per SEBI regulations.
Sai Parenterals Management Change
Sai Parenterals Limited appointed Mr. Ashwani Singh Bisht as Company Secretary and Mr. Arvind Gannimitta as COO. These appointments follow the resignation of Ms. Shivali Aggarwal.
Sai Parenterals Annual General Meeting
Sai Parenterals held its 25th Annual General Meeting on September 10, 2026. Shareholders approved financial statements, director appointments, and various company resolutions.
Sai Parenterals Bags ₹204 Cr Order
Sai Parenterals' subsidiary, Noumed Pharmaceuticals, renewed a 3-year OTC Medicines Supply Agreement with an Australian pharmacy chain, valued at approximately ₹204 Crore.
- Value
- ₹204.0 Cr
- Execution
- 3 years